1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > U.S. Markets for Orthopedic Biologic and Tissue Engineered Products

Biologics and cellular therapies for musculoskeletal injuries—including hard tissue (i.e., bone) and soft tissue (i.e., cartilage, ligaments, and tendons)—represent a billion dollar market that is showing the potential for continued growth. Over the forecast period covered in this report, the estimated value of the U.S. market for orthopedic biologic and tissue engineered products is expected to grow by approximately $984.4 million at a compound annual growth rate (CAGR) of 8.2% to $3,014.1 million; of this holistic market, biologic and cellular therapies for hard musculoskeletal tissue are forecasted to grow at a CAGR of 7.2%, while soft musculoskeletal tissue products will grow at a CAGR of 10.6%.

This report will cover:

emerging and existing cellular therapies for hard and soft musculoskeletal tissue repair and regeneration;
key factors influencing the growth of individual product markets;
estimated market shares and sales among major U.S. suppliers
companies and biotech firms developing novel cellular therapies; and,
major supplier product portfolio analysis in individual product markets.
The scope of the analysis of this report covers companies developing and distributing biologics and novel cellular therapeutics for the treatment of musculoskeletal injuries. Hard tissue musculoskeletal products covered in this report include bone allograft and machined bone, demineralized bone matrix, growth factor-based bone grafts, cellular bone matrices, and select other biologics. Soft tissue musculoskeletal products covered by this report include cartilage regeneration and repair products, ligament and tendon repair technologies, and meniscus repair and regeneration products.

Table Of Contents

U.S. Markets for Orthopedic Biologic and Tissue Engineered Products
TABLE OF CONTENTS

EXECUTIVE SUMMARY
i Methodology

Exhibit ES-1: 2014, US Orthopedic Biologic and Tissue Engineered Products Market, Share by Products

1 OVERVIEW OF MUSCULOSKELETAL DISEASES/DISORDERS
11 Back Pain and Spine Surgery
12 Carpal Tunnel Syndrome
13 Duchenne Muscular Dystrophy
14 Osteoarthritis
15 Osteoporosis and Fractures
16 Rheumatoid Arthritis

Exhibit 1-1: Musculoskeletal Surgery, Procedure Volumes Forecast, by
Type, 2014-2019

2 US MARKETS FOR BIOLOGIC MUSCULOSKELETAL SOFT TISSUE REGENERATION AND REPAIR PRODUCTS
21 Cartilage Regeneration and Repair Technologies
211 Currently Available Products
2111 Arthrex
2112 Vericel
2113 Zimmer
212 Products in Development
2121 CellCoTec
2122 Cytori Therapeutics
2123 Histogenics
2124 ISTO Technologies
2125 Medipost
2126 TETEC
2127 TiGenix
2128 TissueGene
213 Market Forecast
214 Competitive Analysis
22 Ligament and Tendon Repair Technologies
221 Graft-Based Products Overview
222 Tissue Engineering
2221 Biologic Scaffolds
2222 Developmental Biologic Scaffolds
223 Market Forecast
224 Competitive Analysis
23 Meniscus Repair and Regeneration Technologies
231 Products Overview
232 Market Forecast
233 Competitive Analysis
224 US Markets for Biologic Soft Tissue Regeneration and Repair Products

Exhibit 2-1: 2014, Cartilage Repair Procedures
Exhibit 2-2: Cartilage Repair and Regeneration Products, Market Forecast,
2014-2019
Exhibit 2-3: 2014, Knee Cartilage Repair and Regeneration Products Market, Share by Supplier
Exhibit 2-4: 2015, Selected Allografts for Ligament and Tendon Replacement
Exhibit 2-5: 2015, Biologic Scaffolds and Matrices for Ligament and Tendon Repair
Exhibit 2-6: Ligament and Tendon Replacement and Regeneration Products, Market Forecast, 2014-2019
Exhibit 2-7: 2014, Ligament and Tendon Replacement and Regeneration Products Market, Share by Supplier
Exhibit 2-8: 2015, Selected Biologic Meniscal Repair Products
Exhibit 2-9: Meniscal Replacement and Regeneration Products, Market Forecast, 2014-2019
Exhibit 2-10: 2014, Meniscal Replacement and Regeneration Products Market, Share by Supplier
Exhibit 2-11: Musculoskeletal Soft Tissue Biologics Products, Market Forecast, 2014-2019

3 US MARKETS FOR BIOLOGIC MUSCULOSKELETAL HARD TISSUE REGENERATION AND REPAIR
31 Bone Graft and Bone Substitute Products on the Market and Under Development
311 Bone Autograft
312 Bone Allografts and Machined Bone
313 Demineralized Bone Matrix
314 Market Forecast
315 Competitive Analysis
32 Growth Factor-Based Bone Grafts
321 Products Overview
3211 Bioventus
3212 Medtronic
3213 Wright Medical Technology
322 Market Forecast
323 Competitive Analysis
33 Other Biologics Currently Available or in Development
331 Cellular Bone Matrices
3311 AlloSource
3312 Biomet
3313 NuVasive
3314 Orthofix
3315 Osiris Therapeutics
3316 RTI Surgical
332 Cellular Regeneration Therapies in Development for Hard Bone Musculoskeletal Repair
3321 Cerapedics, Inc
3322 Ferring Pharmaceuticals
3323 Mesoblast
333 Market Forecast
334 Competitive Analysis
34 Emerging Areas of Cellular Therapy for Soft and Hard Tissue Repair and Regeneration
341 Bone Marrow Aspirate Concentrate
342 Gene Therapy
3421 Systemic Gene Therapy
3422 Regional Gene Therapy
343 Three-Dimensional Printing
35 US Markets for Musculoskeletal Hard Tissue Regeneration and Repair Products
36 Combined Market Summary for Hard and Soft Tissue Engineering
and Cellular Therapy Products

Exhibit 3-1: 2015, Description and Representative Pricing of Base Allografts Used in Spine Surgery
Exhibit 3-2: 2015, Selected Bone Allograft and Machined Bone Products
Exhibit 3-3: 2015, Selected Demineralized Bone Matrix Products
Exhibit 3-4: Bone Allografts and Synthetic Bone Graft Substitutes, Market Forecast, 2014-2019
Exhibit 3-5: 2014, Bone Allograft Products Market, Share by Supplier
Exhibit 3-6: 2014, Demineralized Bone Matrix Products Market, Share by Supplier
Exhibit 3-7: Growth Factor-Based Products, Market Forecast, 2014-2019
Exhibit 3-8: 2014, Growth Factor-Based Products Market, Share by Supplier
Exhibit 3-9: Stem Cell Matrices and Other Osteobiologic Agents for Bone
Healing and Enhancement of Spinal Fusion, Market
Forecast, 2014-2019
Exhibit 3-10: 2014, Market Shares of Stem Cell Applications for Bone Healing and Spinal Fusion by Application
Exhibit 3-11: 2014, Stem Cell Products and Other Orthobiologics for Bone
Healing and Spinal Fusion, Share by Supplier
Exhibit 3-12: US Biologic Products for Musculoskeletal Hard Tissue Repair and Regeneration, Combined Market Forecast, 2014-2019
Exhibit 3-13: US Hard and Soft Musculoskeletal Tissue Repair and Regeneration, Combined Procedure Volumes, 2014-2019
Exhibit 3-14: US Biologic Products for Musculoskeletal Hard and Soft Tissue Repair and Regeneration, Combined Market
Forecast, 2014-2019

APPENDIX: COMPANY LISTING

BIBLIOGRAPHY

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.